Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 16INDUSTRY 14OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 4Recurrence 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Surgical Procedures, Operative 2Dexamethasone 2temoporfin 1pomalidomide 1pembrolizumab 1nimotuzumab 1liposomal doxorubicin 1ledipasvir 1ibrutinib 1golimumab 1Vinorelbine 1Tomography, X-Ray Computed 1Thalidomide 1Sofosbuvir 1Rituximab 1Ribavirin 1Radiotherapy 1Radiation 1Paclitaxel 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Mitoxantrone 1Mastectomy 1Irinotecan 1Infliximab 1Immunotherapy, Adoptive 1Hematologic Tests 1Drug Therapy 1Docetaxel 1Diagnostic Imaging 1Dermoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Recurrence × Azacitidine × Clear all
NCT00412919 2013-12-16

Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Bayside Health

Phase 2 Terminated
7 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡